The British pharmaceutical company has promised 80 million doses, but they can only produce 31 million.

Coronavirus – the second year

It has been more than a year since the Chinese authorities informed the WHO of the emergence of a new, rapidly spreading virus. Since then, there has hardly been a person in the world who has not heard the term Covid-19, and more and more people are mourning a family member or friend with whom the new disease ended as stocks collapsed in weeks and our entire lives were rewritten. by the epidemic. By now, the vaccines have been completed, which in turn raises not only hope, but again many questions, while not only stopping the virus, but threatening another mutation as well. You will find the details of this fight in our series of articles.

AstraZeneca, a British pharmaceutical company, reduced vaccine shipments to the European Union by 60 percent to 31 million doses in the first quarter due to manufacturing problems, said a senior EU leader. Reuters with a British news agency.

The company plans to deliver around 80 million doses of the vaccine to the EU-27 by the end of March

– informed the person responsible for the negotiations that he requested that his name be withheld.

Hungary has previously granted a temporary permit for the AstraZeneca vaccine and Russian Sputnik V, but it is still questionable when they can start vaccinating the population with them. Sputnik does not yet have a permit from the NNK and the British vaccine cannot be transported without approval from the European Medicines Agency. You can read the details here.

The pharmaceutical company had previously promised to deliver more than 80 million doses, to the EU, in the second quarter, but has now been unable to set delivery targets for the April-June period due to manufacturing problems, the authority said. The company had to reduce deliveries according to the competent authority due to production problems at its vaccine plant operated by its partner Novasep in Belgium.

The drop in deliveries was also confirmed by an AstraZeneca spokesperson. AFP French news agency.

The European Medicines Agency (EMA) announced on January 12 that it had received an application for authorization for a vaccine developed by AstraZeneca and the University of Oxford. The EMA then announced that a decision would be made on January 29. “Although there was no deadline to start shipping our vaccine, even if we obtain the European license, the quantities will be lower than planned due to decreased performance at one of the production sites in the European supply chain,” said the spokesman.

The European Commission initially seized 400 million doses of vaccine.

EU Health Commissioner Stella Kiriakides expressed her dissatisfaction with the drop in deliveries in a Twitter message. “By maintaining conditional authorization, we insisted on a precise delivery schedule so that member states could plan the vaccination program,” he wrote.

The so-called Oxford / AstraZeneca vector vaccine is cheaper to produce than those based on the RNA messenger method, and it is easier to transport and store.



The number of independent power editorial boards is steadily declining, and those that still exist are trying to stay afloat in a growing headwind. At HVG we persevere, we do not give in to pressure and we bring national and international news every day.

That is why we ask you, our readers, to support us, support us, join our membership and renew it!

And we promise to keep doing our best for you in all circumstances!